{"success":true,"data":{"pressRelease":{"id":"73364","rtpr_id":"nACS5Y0MYa","ticker":"LEXX","exchange":"NASDAQ","all_tickers":["LEXX"],"title":"Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule","author":"ACCESSWIRE","published_at":"2026-06-25T13:10:00.812Z","article_body":"KELOWNA, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 25,\n2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the \"Company\" or \"Lexaria\"), a\nglobal innovator in drug delivery platforms, announces that dosing began on\nschedule on June 14(th) with Human Pilot Study #7 (GLP-1-H26-7) that is\nevaluating two oral DehydraTECH-semaglutide (\"DHT-sema\") compositions against\nNovo Nordisk's® (\"Novo\") commercially available Wegovy® tablets, over a\n5-week duration (the \"Study\").\n\nLexaria is seeking to preserve the superior safety and tolerability profiles\nevidenced in its previous glucagon-like peptide-1 (\"GLP-1\") studies such as\nHuman Study #4 (GLP-1-H24-4 (https://pr.report/mz07)), combined with\npharmacokinetic (\"PK\") performance that matches or exceeds the Wegovy® tablet\ncontrol. Previous Lexaria salcaprozate sodium (\"SNAC\")-inclusive DHT-sema\nsingle dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1\n(https://pr.report/mz08) and GLP-1-H24-2 (https://pr.report/mz09)) evidenced\nPK performance that matched or exceeded the Rybelsus® control arm and also\nevidenced noteworthy safety and tolerability profiles.\n\nThe results of this Study are expected to be carefully reviewed by the\npharmaceutical industry in order to evaluate the possibility of entering into\ncommercial relationships focused on Lexaria's proprietary DehydraTECH™\ntechnology.\n\nThe Study is investigating three separate arms to assess safety & tolerability\nas well as PK properties that will compare SNAC-inclusive, DHT-sema\ncompositions formulated in both tablet and capsule formats to commercially\navailable Wegovy® tablets. The Study is being conducted under fasted pre-dose\nconditions similar to the advised administration criteria of Novo's oral\nsemaglutide products. The 5-week dosing duration was selected in order to\nallow for achievement of steady state concentration levels\n(https://pr.report/mz0a), meaning that the semaglutide blood quantities in\neach arm will be expected to reach an equilibrium level that balances drug\ninput with natural bodily elimination.\n\nThe Study is exploring several new DehydraTECH™ enhancements not previously\nevaluated, which include but are not limited to the following two main\nimprovements:\n\n(1) First, an oral tablet DHT-sema composition will be used by Lexaria for the\nfirst time, as opposed to only the capsule compositions administered in all\nour previous DehydraTECH™ GLP-1 studies. Novo's Rybelsus® and Wegovy® oral\nsemaglutide medications use specially formulated tablets designed to\ntemporarily adhere to the stomach lining and disintegrate and dissolve\nreleasing agents in a focal manner that aids in optimizing absorption of\nsemaglutide into the human body. For the first time ever, Lexaria has\nattempted to mimic and integrate certain physical properties of the Rybelsus®\nand Wegovy® SNAC-inclusive tablet delivery modality into its DHT-sema tablets\nto follow established industry standards and thereby increase the likelihood\nof subsequent commercial pharmaceutical relationships.\n\n(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be\nformulated with SNAC, which will be the first time these formulations will be\nevaluated over a multi-dose, multi-week time period in humans. The five-week\ndosing duration of the Study is expected to be long enough to reach so-called\nsteady-state (https://pr.report/mz0b), which is when drug concentrations in\nthe body reach a constant concentration. As noted above, Human Pilot Studies\n#1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), conducted in 2024 and 2025 which\nincorporated SNAC (but did not use tablets), were limited by single-dose study\ndesigns and therefore of much shorter duration.\n\nThe Study is fully funded from existing corporate resources.\n\nAbout Lexaria Bioscience Corp. & DehydraTECH™\n\nDehydraTECH(TM) is Lexaria's patented drug delivery formulation and processing\nplatform technology which improves the way a wide variety of drugs enter the\nbloodstream, always through oral delivery. DehydraTECH(TM) has repeatedly\nevidenced the ability to increase bio-absorption, reduce side-effects, and\ndeliver some drugs more effectively across the blood brain barrier. Lexaria\noperates a licensed in-house research laboratory and holds a robust\nintellectual property portfolio with 66 patents granted and additional patents\npending worldwide. For more information, please visit\nwww.lexariabioscience.com.\n\nCAUTION REGARDING FORWARD-LOOKING STATEMENTS\n\nThis press release includes forward-looking statements. Statements as such\nterm is defined under applicable securities laws. These statements may be\nidentified by words such as \"anticipate,\" \"if,\" \"believe,\" \"plan,\" \"estimate,\"\n\"expect,\" \"intend,\" \"may,\" \"could,\" \"should,\" \"will,\" and other similar\nexpressions. Such forward-looking statements in this press release include,\nbut are not limited to, statements by the Company relating to the Company's\nability to carry out research initiatives, receive regulatory approvals or\ngrants or experience positive effects or results from any research or study.\nSuch forward-looking statements are estimates reflecting the Company's best\njudgment based upon current information and involve a number of risks and\nuncertainties, and there can be no assurance that the Company will actually\nachieve the plans, intentions, or expectations disclosed in these\nforward-looking statements. As such, you should not place undue reliance on\nthese forward-looking statements. Factors which could cause actual results to\ndiffer materially from those estimated by the Company include, but are not\nlimited to, government regulation and regulatory approvals, managing and\nmaintaining growth, the effect of adverse publicity, litigation, competition,\nscientific discovery, the patent application and approval process, potential\nadverse effects arising from the testing or use of products utilizing the\nDehydraTECH technology, the Company's ability to maintain existing\ncollaborations and realize the benefits thereof, delays or cancellations of\nplanned R&D that could occur related to pandemics or for other reasons, and\nother factors which may be identified from time to time in the Company's\npublic announcements and periodic filings with the US Securities and Exchange\nCommission on EDGAR. The Company provides links to third-party websites only\nas a courtesy to readers and disclaims any responsibility for the\nthoroughness, accuracy or timeliness of information at third-party websites.\nThere is no assurance that any of Lexaria's postulated uses, benefits, or\nadvantages for the patented and patent-pending technology will in fact be\nrealized in any manner or in any part. No statement herein has been evaluated\nby the Food and Drug Administration (FDA). Lexaria-associated products are not\nintended to diagnose, treat, cure or prevent any disease. Any forward-looking\nstatements contained in this release speak only as of the date hereof, and the\nCompany expressly disclaims any obligation to update any forward-looking\nstatements or links to third-party websites contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise, except as otherwise required by law.\n\nINVESTOR CONTACT:\nGeorge Jurcic - Head of Investor Relations\nir@lexariabioscience.com\nPhone: 250-765-6424, ext. 202\n\nSOURCE: Lexaria Bioscience Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule-1182053)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS5Y0MYa","title":"Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule","author":"ACCESSWIRE","ticker":"LEXX","created":"2026-06-25T13:10:00.812Z","tickers":["LEXX"],"exchange":"NASDAQ","article_body":"KELOWNA, BC / ACCESS Newswire (https://www.accessnewswire.com/) / June 25,\n2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the \"Company\" or \"Lexaria\"), a\nglobal innovator in drug delivery platforms, announces that dosing began on\nschedule on June 14(th) with Human Pilot Study #7 (GLP-1-H26-7) that is\nevaluating two oral DehydraTECH-semaglutide (\"DHT-sema\") compositions against\nNovo Nordisk's® (\"Novo\") commercially available Wegovy® tablets, over a\n5-week duration (the \"Study\").\n\nLexaria is seeking to preserve the superior safety and tolerability profiles\nevidenced in its previous glucagon-like peptide-1 (\"GLP-1\") studies such as\nHuman Study #4 (GLP-1-H24-4 (https://pr.report/mz07)), combined with\npharmacokinetic (\"PK\") performance that matches or exceeds the Wegovy® tablet\ncontrol. Previous Lexaria salcaprozate sodium (\"SNAC\")-inclusive DHT-sema\nsingle dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1\n(https://pr.report/mz08) and GLP-1-H24-2 (https://pr.report/mz09)) evidenced\nPK performance that matched or exceeded the Rybelsus® control arm and also\nevidenced noteworthy safety and tolerability profiles.\n\nThe results of this Study are expected to be carefully reviewed by the\npharmaceutical industry in order to evaluate the possibility of entering into\ncommercial relationships focused on Lexaria's proprietary DehydraTECH™\ntechnology.\n\nThe Study is investigating three separate arms to assess safety & tolerability\nas well as PK properties that will compare SNAC-inclusive, DHT-sema\ncompositions formulated in both tablet and capsule formats to commercially\navailable Wegovy® tablets. The Study is being conducted under fasted pre-dose\nconditions similar to the advised administration criteria of Novo's oral\nsemaglutide products. The 5-week dosing duration was selected in order to\nallow for achievement of steady state concentration levels\n(https://pr.report/mz0a), meaning that the semaglutide blood quantities in\neach arm will be expected to reach an equilibrium level that balances drug\ninput with natural bodily elimination.\n\nThe Study is exploring several new DehydraTECH™ enhancements not previously\nevaluated, which include but are not limited to the following two main\nimprovements:\n\n(1) First, an oral tablet DHT-sema composition will be used by Lexaria for the\nfirst time, as opposed to only the capsule compositions administered in all\nour previous DehydraTECH™ GLP-1 studies. Novo's Rybelsus® and Wegovy® oral\nsemaglutide medications use specially formulated tablets designed to\ntemporarily adhere to the stomach lining and disintegrate and dissolve\nreleasing agents in a focal manner that aids in optimizing absorption of\nsemaglutide into the human body. For the first time ever, Lexaria has\nattempted to mimic and integrate certain physical properties of the Rybelsus®\nand Wegovy® SNAC-inclusive tablet delivery modality into its DHT-sema tablets\nto follow established industry standards and thereby increase the likelihood\nof subsequent commercial pharmaceutical relationships.\n\n(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be\nformulated with SNAC, which will be the first time these formulations will be\nevaluated over a multi-dose, multi-week time period in humans. The five-week\ndosing duration of the Study is expected to be long enough to reach so-called\nsteady-state (https://pr.report/mz0b), which is when drug concentrations in\nthe body reach a constant concentration. As noted above, Human Pilot Studies\n#1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), conducted in 2024 and 2025 which\nincorporated SNAC (but did not use tablets), were limited by single-dose study\ndesigns and therefore of much shorter duration.\n\nThe Study is fully funded from existing corporate resources.\n\nAbout Lexaria Bioscience Corp. & DehydraTECH™\n\nDehydraTECH(TM) is Lexaria's patented drug delivery formulation and processing\nplatform technology which improves the way a wide variety of drugs enter the\nbloodstream, always through oral delivery. DehydraTECH(TM) has repeatedly\nevidenced the ability to increase bio-absorption, reduce side-effects, and\ndeliver some drugs more effectively across the blood brain barrier. Lexaria\noperates a licensed in-house research laboratory and holds a robust\nintellectual property portfolio with 66 patents granted and additional patents\npending worldwide. For more information, please visit\nwww.lexariabioscience.com.\n\nCAUTION REGARDING FORWARD-LOOKING STATEMENTS\n\nThis press release includes forward-looking statements. Statements as such\nterm is defined under applicable securities laws. These statements may be\nidentified by words such as \"anticipate,\" \"if,\" \"believe,\" \"plan,\" \"estimate,\"\n\"expect,\" \"intend,\" \"may,\" \"could,\" \"should,\" \"will,\" and other similar\nexpressions. Such forward-looking statements in this press release include,\nbut are not limited to, statements by the Company relating to the Company's\nability to carry out research initiatives, receive regulatory approvals or\ngrants or experience positive effects or results from any research or study.\nSuch forward-looking statements are estimates reflecting the Company's best\njudgment based upon current information and involve a number of risks and\nuncertainties, and there can be no assurance that the Company will actually\nachieve the plans, intentions, or expectations disclosed in these\nforward-looking statements. As such, you should not place undue reliance on\nthese forward-looking statements. Factors which could cause actual results to\ndiffer materially from those estimated by the Company include, but are not\nlimited to, government regulation and regulatory approvals, managing and\nmaintaining growth, the effect of adverse publicity, litigation, competition,\nscientific discovery, the patent application and approval process, potential\nadverse effects arising from the testing or use of products utilizing the\nDehydraTECH technology, the Company's ability to maintain existing\ncollaborations and realize the benefits thereof, delays or cancellations of\nplanned R&D that could occur related to pandemics or for other reasons, and\nother factors which may be identified from time to time in the Company's\npublic announcements and periodic filings with the US Securities and Exchange\nCommission on EDGAR. The Company provides links to third-party websites only\nas a courtesy to readers and disclaims any responsibility for the\nthoroughness, accuracy or timeliness of information at third-party websites.\nThere is no assurance that any of Lexaria's postulated uses, benefits, or\nadvantages for the patented and patent-pending technology will in fact be\nrealized in any manner or in any part. No statement herein has been evaluated\nby the Food and Drug Administration (FDA). Lexaria-associated products are not\nintended to diagnose, treat, cure or prevent any disease. Any forward-looking\nstatements contained in this release speak only as of the date hereof, and the\nCompany expressly disclaims any obligation to update any forward-looking\nstatements or links to third-party websites contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise, except as otherwise required by law.\n\nINVESTOR CONTACT:\nGeorge Jurcic - Head of Investor Relations\nir@lexariabioscience.com\nPhone: 250-765-6424, ext. 202\n\nSOURCE: Lexaria Bioscience Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule-1182053)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-25T13:10:00.89393166Z","server_sent_at_ms":1782393000893},"received_at":"2026-06-25T13:10:00.945Z","source_url":"https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule-1182053"},"analysis":{"id":"62729","press_release_id":"73364","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Pilot study results are not guaranteed","Partnership opportunities are hypothetical and depend on study outcomes"],"eventType":"clinical_trial","narrative":"Lexaria announced the initiation of dosing for Human Pilot Study #7 (GLP-1-H26-7), evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets over a 5-week duration.\n\nThis study introduces new tablet formulations and evaluates pharmacokinetics under fasted conditions, aiming to match or exceed the performance of commercially available GLP-1 products.\n\nThe results are intended to support discussions with potential pharmaceutical partners regarding commercial licensing of the DehydraTECH technology.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Dosing initiated on enhanced GLP-1 study; data readout will drive future partnership discussions."},"keyFigures":{"drugName":"DehydraTECH-semaglutide (DHT-sema)","phaseOfTrial":"Human Pilot Study #7"},"quotedText":"","namedEntities":{"people":[{"name":"George Jurcic","role":"Head of Investor Relations"}],"products":["DehydraTECH","Wegovy","Rybelsus"],"companies":[{"name":"Lexaria Bioscience Corp.","ticker":"LEXX"},{"name":"Novo Nordisk","ticker":"NVO","relationship":"competitor"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Initiation of dosing in Human Pilot Study #7 represents a key operational milestone for Lexaria's DehydraTECH-semaglutide program. The study introduces new tablet formulations and multi-dose steady-state analysis, marking a technical advancement from previous single-dose studies. While not a binary regulatory event, it is material to the company's value proposition and potential for future partnerships."},"tickerRelevance":{"others":[{"ticker":"NVO","relevance":"competitor"}],"primary":"LEXX"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"clinical-milestone","sectorWeight":"biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Lexaria announced the initiation of dosing for Human Pilot Study #7 (GLP-1-H26-7), evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets over a 5-week duration.\n\nThis study introduces new tablet formulations and evaluates pharmacokinetics under fasted conditions, aiming to match or exceed the performance of commercially available GLP-1 products.\n\nThe results are intended to support discussions with potential pharmaceutical partners regarding commercial licensing of the DehydraTECH technology.","key_figures":{"drugName":"DehydraTECH-semaglutide (DHT-sema)","phaseOfTrial":"Human Pilot Study #7"},"named_entities":{"people":[{"name":"George Jurcic","role":"Head of Investor Relations"}],"products":["DehydraTECH","Wegovy","Rybelsus"],"companies":[{"name":"Lexaria Bioscience Corp.","ticker":"LEXX"},{"name":"Novo Nordisk","ticker":"NVO","relationship":"competitor"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-25T14:01:28.762Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"micro-cap","eventGravity":"clinical-milestone","sectorWeight":"biotech"}},"durationMs":55345,"modelName":"george-droid-qwen-72b"}}